120 related articles for article (PubMed ID: 37318494)
21. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
Bayraktar S; Hernadez-Aya LF; Lei X; Meric-Bernstam F; Litton JK; Hsu L; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(5):1202-11. PubMed ID: 21800293
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment.
Essa NM; Salem HF; Elgendy MO; Gabr A; Omran MM; Hassan NA; Tashkandi HM; Harakeh S; Boshra MS
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233373
[TBL] [Abstract][Full Text] [Related]
23. Glucose promotes breast cancer aggression and reduces metformin efficacy.
Wahdan-Alaswad R; Fan Z; Edgerton SM; Liu B; Deng XS; Arnadottir SS; Richer JK; Anderson SM; Thor AD
Cell Cycle; 2013 Dec; 12(24):3759-69. PubMed ID: 24107633
[TBL] [Abstract][Full Text] [Related]
24. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
[TBL] [Abstract][Full Text] [Related]
25. Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial.
Zhang J; Ma X; Li Y; Liu R; Li Y; Zhang P; Ren W; Cui P; Wang B; Zhang M; Jin Y; Li X; Wang S
Maturitas; 2020 Jul; 137():1-6. PubMed ID: 32498930
[TBL] [Abstract][Full Text] [Related]
26. Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Winters B; Plymate S; Zeliadt SB; Holt S; Zhang X; Hu E; Lin DW; Morrissey C; Wooldridge B; Gore JL; Porter MP; Wright JL
Prostate; 2015 Nov; 75(15):1694-703. PubMed ID: 26201966
[TBL] [Abstract][Full Text] [Related]
27. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
Cusi K; Consoli A; DeFronzo RA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
[TBL] [Abstract][Full Text] [Related]
28. [Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids].
Vondra K; Hampl R; Nĕmcová D; Hill M; Hoza J; Kot'átková A; Stárka L; Vrbíková J; Zamrazil V
Cas Lek Cesk; 2002 Feb; 141(3):89-95. PubMed ID: 11925670
[TBL] [Abstract][Full Text] [Related]
29. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
Campagnoli C; Berrino F; Venturelli E; Abbà C; Biglia N; Brucato T; Cogliati P; Danese S; Donadio M; Zito G; Pasanisi P
Clin Breast Cancer; 2013 Dec; 13(6):433-8. PubMed ID: 24267731
[TBL] [Abstract][Full Text] [Related]
30. High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells.
Varghese S; Samuel SM; Varghese E; Kubatka P; Büsselberg D
Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30626087
[TBL] [Abstract][Full Text] [Related]
31. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Goodwin PJ; Stambolic V
Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
[TBL] [Abstract][Full Text] [Related]
32. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
[TBL] [Abstract][Full Text] [Related]
33. Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.
Xu C; Xu Y; Shen Z; Zhou H; Xiao J; Huang T
Int Urol Nephrol; 2018 Apr; 50(4):611-617. PubMed ID: 29460133
[TBL] [Abstract][Full Text] [Related]
34. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
[TBL] [Abstract][Full Text] [Related]
36. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
37. Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome.
Kowalska I; Kinalski M; Straczkowski M; Wolczyski S; Kinalska I
Eur J Endocrinol; 2001 May; 144(5):509-15. PubMed ID: 11331217
[TBL] [Abstract][Full Text] [Related]
38. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
39. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
Malki A; Youssef A
Oncol Res; 2011; 19(6):275-85. PubMed ID: 21776823
[TBL] [Abstract][Full Text] [Related]
40. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
